Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

This study has been completed.
Information provided by (Responsible Party):
Fernando Cabanillas, Auxilio Mutuo Cancer Center Identifier:
First received: February 21, 2012
Last updated: July 11, 2012
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2008
  Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)